I'm sorry I can't be more definite about the number, but of course I threw the brochure away after reading it.
Well, last year before it was halted I had recommended to the head neuro at my clinic that they add an infusion center to get some of this extra money. His reply was that "there is no money to be made" in doing the infusions. And, in fact, I saw that the insurance doesn't allow much for the infusion after the in-network writeoff is taken. The only people paying massive charges are those without insurance or have to go out-of-network. There should be minimal markup on the drug and only a small amount for the infusion. Maybe there will be more now that there is a known risk.leeeeeway wrote:Needless to say (so I always wonder why I do) there is bound to be a great deal of markup for whoever gives the med...I think the world of this doc but let there be no mistake there is big profit in it for her. I have heard (from the Biogen rep, actually) that she has the largest number of MS patients in Northern Colorado so I'm not sure if we would have a center here otherwise. I did get Tysabri at the hospital here before but with this extra layer of bureaucracy from the FDA it's a whole new game...
Interesting point Batpere about the markup on the drug...I wonder what part Medicare plays in that, too. I will start asking questions...
Since the drug cos wrote part D I hope they are enjoying it...it sure is one screwed up mess. I believe strongly in profit but this is way past unfair...
Coram, Inc. Infusion Suites Now Providing Tysabri Infusions
Wednesday August 23, 6:32 pm ET
DENVER, Aug. 23, 2006 (PRIMEZONE) -- Coram, Inc., a leading national provider of specialty home infusion and specialty pharmaceutical distribution services, has announced that it has been approved to provide Tysabri(r) (natalizumab), the monotherapy treatment for relapsing forms of multiple sclerosis (MS). Coram treated its first Tysabri patient at its Boise, Idaho branch on August 14, 2006. Currently, Tysabri is offered at select Coram Infusion Suites throughout the country; it is anticipated the treatment will be available through all Coram suites by the end of September, 2006.
``We are pleased to add Tysabri to the extensive list of treatments available at our infusion suites,'' said John J. Arlotta, Coram's Chairman and CEO. ``Coram's 25-year history as a provider of specialty infusion services makes us the perfect choice for the administration of Tysabri, and our nationwide network of infusion suites provides patients with a safe, convenient environment in which to receive these treatments.''
Reintroduced June 5, 2006 by Elan and Biogen Idec, Tysabri is indicated for patients with relapsing forms of MS to slow the worsening of disabilities associated with the disease and to decrease the number of exacerbations. Generally, it is prescribed for patients who don't respond to or tolerate other treatments for MS.
Tysabri is administered through a highly restricted distribution program called the TOUCH(tm) Prescribing Program. With over 50 current and planned ambulatory infusion suites throughout the country, Coram will have the capability to perform Tysabri treatments nationwide.
Coram is a leading national provider of specialty home infusion and specialty pharmaceutical distribution services. With more than 70 full-service branch pharmacies, the company offers both national presence and comprehensive local coverage. Coram's 25 years of experience, clinical expertise and commitment to positive outcomes has earned it a reputation for excellence among patients, clinicians and payors nationwide. The company is nationally accredited by the Accreditation Commission for Health Care, Inc. For more information about Coram, visit http://www.coramhc.com or call 1.800.CoramHC.
- Similar Topics
- Last post